Welcome to our dedicated page for Regeneron Pharmaceuticals news (Ticker: REGN), a resource for investors and traders seeking the latest updates and insights on Regeneron Pharmaceuticals stock.
Regeneron Pharmaceuticals Inc. develops and commercializes biotechnology medicines for serious diseases across eye disease, allergic and inflammatory conditions, cancer, cardiovascular and metabolic disease, neurological disease, hematologic conditions, infectious disease and rare disease. News about REGN commonly covers marketed products and pipeline programs such as EYLEA, EYLEA HD, Dupixent, Praluent, Libtayo, Kevzara, Otarmeni and investigational therapies developed through antibody, genetic medicine and RNA-based approaches.
Recurring company updates include financial results, FDA and European regulatory approvals, clinical trial data, label expansions, collaboration and licensing activity, product-access and pricing arrangements, share repurchase authorizations and corporate responsibility recognition. Regeneron's disclosures also frequently address its Sanofi collaboration around Dupixent and its use of proprietary technologies such as VelocImmune in drug discovery.
Regeneron Pharmaceuticals and Sanofi announced the approval of Dupixent in China for treating moderate-to-severe atopic dermatitis in adults, addressing the urgent clinical need for new therapies. Recognized as an urgently needed overseas medicine, Dupixent is already approved in 60 countries and has transformed treatment by targeting type 2 inflammation. This approval follows data from a global clinical trial involving nearly 3,000 patients, showing positive safety and efficacy results. The launch aligns with Sanofi's growth strategy in China, with plans for more innovative medicines by 2025.